Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented in a podium session at IMMUNOLOGY2026, taking place April 15–19, 2026, in Boston, Massachusetts. The presentation will highlight early evidence of clinical benefit and pharmacodynamic improvement in patients with ROSAH syndrome, a rare genetic autoinflammatory disease driven by disease-ca